Advocacy intelligence hub — real-time data for patient organizations
Myqorzo: FDA approved
treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms
Camzyos: FDA approved
Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Myqorzo
(aficamten)Orphan drugCytokinetics Inc.
12.1 Mechanism of Action Aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity. Aficamten reduces the force generated b...
Camzyos
(mavacamten)Orphan drugMyoKardia, Inc. (A Wholly-Owned Subsidiary of Bristol Myers Squibb)
Cardiac Myosin Inhibitor [EPC]
12.1 Mechanism of Action Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin ...
Leandro Slipczuk, MD, PhD
Montefiore Medical Center
Thierry Sarda
eMyosound SAS
View all Non-familial hypertrophic cardiomyopathy specialists →